- $31.73m
- $72.46m
- $26.55m
Brief: Celularity Inc Files Appeal Request And Amended Compliance Plan With Nasdaq Hearings Panel
Brief: Celularity Provides Corporate Update
Brief: Celularity Inc. Receives Notice From Nasdaq Confirms Intention To File An Appeal
Brief: Celularity Got Notice Of Delisting From Nasdaq
Brief: Celularity Inc Announces Receipt Of Nasdaq Notice Regarding Late Form 10-Q Filing
Brief: Celularity Inc. Announces Receipt Of Nasdaq Notice Regarding Late Form 10-K Filing
Brief: Celularity Announces 1-For-10 Reverse Stock Split
Brief: Celularity Confirms Commercialization Agreement With Biocellgraft
Brief: Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Celularity Inc reports results for the quarter ended in June - Earnings Summary
Celularity Inc expected to post a loss of 3 cents a share - Earnings Preview
Celularity Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Celularity Announces $3 Million Offering
Brief: Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3L Ocular For Ophthalmic Applications
Brief: Celularity Inc Enters Into Amended, Restated Senior Secured Loan Agreement With Resorts World
Brief: Celularity Inc - Files Prospectus Related To Offer From Time To Time By Selling Securityholders Of Up To 32.1 Million Shares Of Class A Common Stock
Brief: Celularity Announces $45 Mln Purchase Order, First Middle East Private Label Agreement For Celularity’S Halal-Certified Biomaterial Products
Celularity Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Celularity Announces Advisory Guidance From Tamer Group